Healio and Cardiology Today have curated a list of the most-read news in cardiology and cardiac intervention from 2020.
A HIPAA-compliant, cloud-based telehealth solution that allows physicians to perform their hospital rounds virtually is now available, the digital health platform Zyter announced.
Combining PCI and TAVR significantly increases the risk of bleeding compared with a coronary intervention alone, and that excess hazard is not captured well by the CathPCI risk model, data from a large New York City hospital show.
Few studies have evaluated if diastolic function could predict outcomes in patients with aortic stenosis. The authors aimed to assess the association between diastolic dysfunction (DD) and outcomes in patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR).
Greater sodium intake on a national level is associated with a longer average life expectancy and reduced all-cause mortality, according to an ecological study based on data from 181 countries.
Among patients who underwent PCI with a sirolimus-eluting stent, short-term and long-term dual antiplatelet therapy conferred similar rates of target vessel failure, researches reported.
Abiomed (NASDAQ: ABMD) announces the first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, a compact cardiopulmonary bypass system. The advanced ECMO technology pumps, oxygenates, and removes carbon dioxide from the blood for patients whose lungs can no longer provide sufficient end-organ oxygenation.
IRVINE, Calif., Dec. 21, 2020 — Edwards Lifesciences (NYSE: EW), today announced that the first patient has been treated in the RESTORE clinical trial, which will evaluate the safety and effectiveness of the investigational HARPOON Beating Heart Mitral Valve Repair System in the United States and Canada.
Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company’s HeartMate 3™ heart pump to be used in pediatric patients with advanced refractory left ventricular heart failure. With the updated labeling, physicians now have additional options for treating this underserved population awaiting a heart transplant or […]
The HeartLight System is a catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI), the gold standard treatment for atrial fibrillation (AF). HeartLight is a treatment option for some patients whose AF is insufficiently controlled with medication.
Stay Up-To-Date on jobs and industry news.
Sign up for the CathLab.com newsletter today!